Mattia Alberti
Overview
Explore the profile of Mattia Alberti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
3
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alberti M, Marcucci A, Biondi F, Chiusolo S, Masini G, Faggioni L, et al.
J Cardiovasc Echogr
. 2025 Feb;
34(4):160-169.
PMID: 39895893
Myocardial injury is a recognized complication of acute pancreatitis, whereas myocarditis has only been occasionally reported and has not been systematically evaluated. We systematically reviewed PubMed literature published up to...
2.
Alberti M, Biondi F, Barletta V, Castiglione V, Bort I, Del Carlo C, et al.
J Cardiovasc Echogr
. 2024 Oct;
34(3):144-148.
PMID: 39444387
Cardiac sarcoidosis is an insidious condition with a highly variable clinical presentation that often mimics other diseases. Its diagnosis is particularly challenging, requiring a high index of suspicion and a...
3.
Biondi F, Alberti M, Montemaggi E, DAlleva A, Madonna R
Thromb Haemost
. 2024 Sep;
PMID: 39299271
Three mutually exclusive entities can underlie a postpulmonary embolism syndrome (PPES): not obstructed postpulmonary embolism syndrome (post-PE dyspnea), chronic thromboembolic pulmonary disease (CTEPD), and chronic thromboembolic pulmonary hypertension (CTEPH). Cardiorespiratory...
4.
Madonna R, Alberti M, Biondi F, Morganti R, Badagliacca R, Vizza C, et al.
Vascul Pharmacol
. 2024 Jul;
155:107291.
PMID: 38985593
No abstract available.
5.
Madonna R, Biondi F, Alberti M, Ghelardoni S, Mattii L, DAlleva A
Biomed Pharmacother
. 2024 Apr;
175():116650.
PMID: 38678962
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new class of glucose-lowering drugs traditionally used to control blood glucose levels in patients with type 2 diabetes mellitus, have been proven to reduce...
6.
Madonna R, Alberti M, Biondi F, Morganti R, Badagliacca R, Vizza C, et al.
Eur J Intern Med
. 2023 Dec;
123:120-126.
PMID: 38042668
Background And Aim: Chronic thromboembolic pulmonary disease (CTEPD) is a progressive condition caused by fibrotic thrombi and vascular remodeling in the pulmonary circulation despite prolonged anticoagulation. We evaluated clinical factors...